Moderate resting hypoxaemia in fibrotic interstitial lung disease

Yet H. Khor, Amelia Harrison, Julien Robinson, Nicole S.L. Goh, Ian Glaspole, Christine F. McDonald

Source: Eur Respir J, 57 (1) 2001563; 10.1183/13993003.01563-2020

Journal Issue: January

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Yet H. Khor, Amelia Harrison, Julien Robinson, Nicole S.L. Goh, Ian Glaspole, Christine F. McDonald. Moderate resting hypoxaemia in fibrotic interstitial lung disease. Eur Respir J, 57 (1) 2001563; 10.1183/13993003.01563-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Nitrofurantoin-induced interstitial lung disease Source: Annual Congress 2012 - Viral infections and rare respiratory infections Year: 2012
Mild parenchymal lung disease is still lung disease Source: Eur Respir J, 56 (5) 2003727; 10.1183/13993003.03727-2020 Year: 2020
Mild parenchymal lung disease is still lung disease Source: Eur Respir J, 56 (5) 2003542; 10.1183/13993003.03542-2020 Year: 2020
Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease Source: Eur Respir J, 55 (2) 1901681; 10.1183/13993003.01681-2019 Year: 2020
Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015
Alveoscopy in diffuse interstitial lung disease Source: Eur Respir J 2007; 30: Suppl. 51, 244s Year: 2007
Pulmonary hypertension in interstitial lung disease Source: Eur Respir J 2008; 31: 1357-1367 Year: 2008
Chronic obstructive pulmonary disease with preserved lung function, severe hypoxemia and emphysema Source: Virtual Congress 2020 – Monitoring of patients with COPD Year: 2020
Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease Source: Eur Respir J, 49 (5) 1602494; 10.1183/13993003.02494-2016 Year: 2017
Rituximab in severe, progressive interstitial lung disease Source: International Congress 2016 – Connective tissue disorders Year: 2016
Clubbing in patients with fibrotic interstitial lung diseases Source: International Congress 2017 – ILDs: clinical problems Year: 2017
Rituximab in severe, treatment-refractory interstitial lung disease Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013
Biomarkers for pulmonary hypertension in interstitial lung disease Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease Year: 2011
Pulmonary vascular response patterns during exercise in interstitial lung disease Source: Eur Respir J 2015; 46: 738-749 Year: 2015
Aquoaporin-1 expression in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013
Biomarkers in pulmonary hypertension associated to interstitial lung disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Pattern of airway inflammation and remodeling in mild chronic obstructive pulmonary disease Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010
Pertechnegas lung clearance in different forms of interstitial lung disease Source: Eur Respir J 2002; 19: 31-36 Year: 2002